Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Net Cash Flow (2020 - 2025)

Bioventus (BVS) has disclosed Net Cash Flow for 6 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 1465.85% year-over-year to $8.9 million, compared with a TTM value of $9.3 million through Dec 2025, up 29.35%, and an annual FY2025 reading of $9.3 million, up 29.35% over the prior year.
  • Net Cash Flow was $8.9 million for Q4 2025 at Bioventus, down from $9.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $102.5 million in Q4 2022 and bottomed at -$41.4 million in Q3 2022.
  • Average Net Cash Flow over 5 years is $4.2 million, with a median of $3.9 million recorded in 2024.
  • The sharpest move saw Net Cash Flow tumbled 583.78% in 2022, then surged 1465.85% in 2025.
  • Year by year, Net Cash Flow stood at -$31.9 million in 2021, then surged by 421.84% to $102.5 million in 2022, then plummeted by 92.59% to $7.6 million in 2023, then plummeted by 92.49% to $571000.0 in 2024, then soared by 1465.85% to $8.9 million in 2025.
  • Business Quant data shows Net Cash Flow for BVS at $8.9 million in Q4 2025, $9.6 million in Q3 2025, and $9.9 million in Q2 2025.